Satiogen Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Satiogen Pharmaceuticals, Inc.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
PerkinElmer(US) has appointed Dr Alan Fletcher vice-president of bio-discovery business development, in its life and analytical sciences business. He will be responsible for developing partnerships and introducing new technologies. Dr Fletcher joins from GE Healthcare were he held a number of positions in its life science and discovery systems business units.
- Other Names / Subsidiaries
- Mirum Pharmaceuticals, Inc.